Rheumatoid arthritis
Conditions
Interventions
Treatment group:The combination of Iguratimod or tofacitinib.
Sponsors
The Fourth Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.The condition satisfies the rheumatoid arthritis classification criteria jointly established by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) in 2010; 2.Meeting any of the following treatment criteria with suboptimal efficacy (DAS28 score indicating moderate to high disease activity): Receiving conventional DMARD therapy, such as methotrexate, for a minimum duration of 3 months; Undergoing treatment with biologic agents, such as TNF inhibitors, for at least 3 months; Receiving treatment with either eramode or tofacitinib monotherapy for a minimum period of 3 months; 3.Understand the procedure and content of the test, and sign the informed consent voluntarily; 4. Age 18 or older; Open to all genders.
Exclusion criteria
Exclusion criteria: 1.Patients who are known to have an allergy to Iguratimod or tofacitinib. 2.Patients who have previously used Iguratimod or tofacitinib and discontinued treatment for safety reasons. 3.At the time of screening, they were in the acute phase of acute infection or chronic infection. 4.At screening, a positive hepatitis B DNA and/or hepatitis C RNA screening is suggestive of viral hepatitis, and only healthy HBsAg positive carriers are not considered as exclusion criteria, and the inclusion of this patient is at the discretion of the investigator. 5.At the time of screening, there was a history of active TB or TB screening suggested latent infection with mycobacterium tuberculosis. 6.Disease or history of congestive heart failure at the time of screening. 7.Patients have been enrolled in other ongoing projects or studies. 8.Severe, progressive, uncontrolled, vital organ and system disorders, and any other condition that the physician deems inappropriate for inclusion in this collection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The achievement rates for ACR20, ACR50, and ACR70.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Erythrocyte sedimentation rate;C-reactive protein; | — |
Countries
China
Contacts
Public ContactChang Jie
The Fourth Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed